Ask AI
ProCE Banner Activity

FAQs: CAR T-Cell Therapy and Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma

Clinical Thought

In this commentary, an expert addresses questions about the selection and sequencing of CAR T-cell therapy and bispecific antibodies in the management of patients with relapsed/refractory multiple myeloma, including approaches used in the Veterans Healthcare System.

Released: April 28, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from Bristol Myers Squibb and Johnson & Johnson.

Bristol Myers Squibb

Johnson & Johnson

Target Audience

This activity is intended for hematologists, oncologists, nurses, physician associates, pharmacists, and other healthcare professionals in VA medical centers caring for patients with relapsed/refractory multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Assess the eligibility of patients with relapsed/refractory MM for CAR T-cell therapy based on patient and disease characteristics, current indications, and expert recommendations

  • Develop individualized treatment strategies leveraging CAR T-cell or bispecific antibody therapies for patients with relapsed/refractory MM after at least 1 prior line of therapy based on clinical data, approvals, expert recommendations, and patient factors

  • Implement strategies supporting equitable access to novel therapies and clinical trials in Black and underserved populations with relapsed/refractory MM

Disclosure

Primary Author

Salyka Sengsayadeth, MD, has no relevant financial relationships to disclose.